For the primary time in a long time, the pharmaceutical trade has been immediately affected by a geopolitical commerce negotiation between the US and the EU.
On 27 July, the US authorities introduced a 15% tariff on branded pharmaceutical merchandise imported from the EU. Regardless of the lower from the unique 30% tariff on prescribed drugs earlier within the yr, this disrupts a long-established follow of the exemption of medicines from tariffs as a result of their significance in public well being. The 15% tariff isn’t anticipated to occur instantly as implementation will likely be depending on a Nationwide Safety investigation relating to pharmaceutical imports.
This commerce deal places the pharmaceutical trade susceptible to shedding between $13bn and $19bn, with penalties that reach past short-term financials. It can drive pharmaceutical firms to make a tradeoff between tightening their revenue margins and growing drug costs, with each paths posing a danger to affected person entry and payer relations.
The imposition of tariffs threatens to raise prices throughout the pharmaceutical worth chain, and will result in a considerable enhance in drug improvement prices, manufacturing, and distribution, with world provide chains for lively pharmaceutical components (APIs), uncooked supplies, and gear immediately uncovered. This disruption might create uncertainty in launch planning, significantly for late-stage property with EU-based manufacturing and manufacturing deliberate for US entry. Firms manufacturing pharmaceutical merchandise in Europe might want to anticipate monetary publicity when planning launches within the US as a result of unfavourable gross-to-net dynamics, weakened pricing leverage with US payers, and slower business uptake as insurers reassess cost-effectiveness as a result of tariffs.
Analysis and improvement budgets are already underneath strain, and could also be additional strained as pharmaceutical firms might should divert funds to firefight the affect of the tariffs. This might hinder innovation and pipeline funding, decreasing the much-needed tempo of therapeutic innovation throughout the trade.
Earlier within the yr, the US administration did sign tariffs for pharmaceutical imports might grow to be an actual risk; this was met with proactive US funding from main pharmaceutical firms to onshore manufacturing within the US to cut back publicity. Most just lately, in July 2025, Biogen introduced a $2bn funding into North Carolina, strengthening its US manufacturing place. Different pharmaceutical firms equivalent to Johnson & Johnson, AstraZeneca, and Eli Lilly have additionally elevated their funding in US manufacturing, with investments of $55bn, $50bn, and $27bn, respectively.